NCT04429529View on ClinicalTrials.gov

Safety of TY027, a Treatment for COVID-19, in Humans

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

June 9, 2020

Primary Completion Date

November 19, 2020

Study Completion Date

January 20, 2021

Conditions
Coronavirus Disease-2019 (COVID-19)
Interventions
BIOLOGICAL

TY027

TY027 Injection, (100 mg/5 mL/Vial), SARS-CoV-2 Monoclonal Antibody (mAb)

OTHER

0.9% Saline

Placebo

Trial Locations (1)

169608

SingHealth Investigational Medicine Unit, Singapore

All Listed Sponsors
lead

Tychan Pte Ltd.

INDUSTRY

NCT04429529 - Safety of TY027, a Treatment for COVID-19, in Humans | Biotech Hunter | Biotech Hunter